Abstract Globally, ovarian cancer is the third most common female malignancies causing mortality. Cisplatin is the first line of therapy for treating ovarian cancer (OC), its therapeutic efficacy is severely limited owing to emergence of drug resistance. Chemoresistance may be acquired or intrinsic and overcoming chemoresistance is the key challenge in OC therapy. Nanotherapeutic interventions against cancer offers unprecedented opportunities for overcoming the limitations of conventional chemotherapies. The heterogeneity and complexity of tumors necessitates using improved strategies to understand nano–bio-interactions that remain important roadblocks to future clinical translation and commercialization. Diverse mechanisms of cisplatin sensitivity/ resistance involve complex processes including drug transport, efflux of drug, detoxification of the drug, response to DNA damage, increased DNA repair, epigenetic changes and autophagy. MicroRNAs (miRNAs) are crucial in determining cisplatin resistance or sensitivity and their role in tumor progression, metastasis needs to be explored to evolve better therapeutic strategies. This review comprehensively summarizes the mechanisms involved in cancer chemoresistance and strategies to sensitize/overcome cisplatin resistance in ovarian cancer.
Mittal et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: